Gilead Sciences Inc. and LEO Pharma have partnered to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and activator of transcription 6) ...

While LEO Pharma maintains worldwide rights to topical formulations in dermatology and may co-commercialize oral medicines ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of the latter’s small molecule oral signal transducer and activator of ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 and IL-13 signaling, which in turn are known inflammatory targets.

LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...

Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule ...

Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This collaboration aims to develop treatments for patients suffering from inflammatory ...

Gilead Sciences and Danish dermatology specialist LEO Pharma announced a strategic partnership, marking another move outside its traditional infectious disease area for the US antiviral giant.

and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of transcription 6) programs for the potential ...

Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders -- -- Gilead ...

Gilead Sciences Inc. and Leo Pharma A/S have established a strategic partnership to accelerate the development and commercialization of Leo’s small-molecule oral STAT6 programs for the treatment of ...